Abstract
Objective: While the survival of extremely premature infants has improved over the past decades, the rate of complications – especially for bronchopulmonary dysplasia (BPD) – remains un-acceptably high. Over the past 50 years, no safe therapy has had a substantial impact on the incidence and severity of BPD.Methods: This may stem from the multifactorial disease pathogenesis and the increasing lung imma-turity. Mesenchymal Stromal Cells (MSCs) display pleiotropic effects and show promising results in neonatal rodents in preventing or rescuing lung injury without adverse effects. Early phase clinical trials are now underway to determine the safety and efficacy of this therapy in extremely premature infants.Results and Conclusion: This review summarizes our current knowledge about MSCs, their mecha-nism of action and the results of preclinical studies that provide the rationale for early phase clinical trials and discuss remaining gaps in our knowledge
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
